The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of GoodRx Holdings Inc (NASDAQ: GDRX) closed at $2.83 in the last session, up 2.91% from day before closing price of $2.75. In other words, the price has increased by $2.91 from its previous closing price. On the day, 3.06 million shares were traded. GDRX stock price reached its highest trading level at $2.905 during the session, while it also had its lowest trading level at $2.735.
Ratios:
We take a closer look at GDRX’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.51 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.42. For the most recent quarter (mrq), Quick Ratio is recorded 3.11 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.91 whereas as Long-Term Debt/Eq ratio is at 0.89.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Underweight rating and assigned the stock a target price of $3.
On December 04, 2024, Mizuho started tracking the stock assigning a Neutral rating and target price of $5.Mizuho initiated its Neutral rating on December 04, 2024, with a $5 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 15 ’25 when Spectrum Equity VII, L.P. sold 23,771 shares for $4.00 per share. The transaction valued at 95,103 led to the insider holds 0 shares of the business.
Spectrum VII Co-Investment Fun bought 8,569 shares of GDRX for $34,447 on Oct 15 ’25. On Oct 15 ’25, another insider, Spectrum VII Investment Manage, who serves as the Affiliate of the company, bought 15,202 shares for $4.02 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 983283456 and an Enterprise Value of 1232201472. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 32.95, and their Forward P/E ratio for the next fiscal year is 6.49. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.44. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.20 while its Price-to-Book (P/B) ratio in mrq is 1.61. Its current Enterprise Value per Revenue stands at 1.539 whereas that against EBITDA is 9.284.
Stock Price History:
The Beta on a monthly basis for GDRX is 1.50, which has changed by -0.37641722 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $5.81, while it has fallen to a 52-week low of $2.61. The 50-Day Moving Average of the stock is -4.17%, while the 200-Day Moving Average is calculated to be -29.50%.
Shares Statistics:
According to the various share statistics, GDRX traded on average about 3.18M shares per day over the past 3-months and 2291650 shares per day over the past 10 days. A total of 98.30M shares are outstanding, with a floating share count of 86.84M. Insiders hold about 74.41% of the company’s shares, while institutions hold 15.18% stake in the company. Shares short for GDRX as of 1765756800 were 7810985 with a Short Ratio of 2.46, compared to 1763078400 on 7291578. Therefore, it implies a Short% of Shares Outstanding of 7810985 and a Short% of Float of 8.290000000000001.
Earnings Estimates
The dynamic stock of GoodRx Holdings Inc (GDRX) is currently being evaluated by a team of 12.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.09, with high estimates of $0.11 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.38 and $0.34 for the fiscal current year, implying an average EPS of $0.36. EPS for the following year is $0.44, with 12.0 analysts recommending between $0.5 and $0.38.
Revenue Estimates
According to 12 analysts,. The current quarter’s revenue is expected to be $192.82M. It ranges from a high estimate of $194.7M to a low estimate of $191M. As of. The current estimate, GoodRx Holdings Inc’s year-ago sales were $198.58MFor the next quarter, 12 analysts are estimating revenue of $193.75M. There is a high estimate of $201.06M for the next quarter, whereas the lowest estimate is $183.37M.
A total of 14 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $796.7M, while the lowest revenue estimate was $793.2M, resulting in an average revenue estimate of $794.7M. In the same quarter a year ago, actual revenue was $792.32MBased on 15 analysts’ estimates, the company’s revenue will be $818.97M in the next fiscal year. The high estimate is $849.8M and the low estimate is $789.43M.
